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Background
The HIV cellular receptor, CD4, is not subject to the high
rate of mutation found in viral gene products. Therefore
antibodies that target the gp120 binding domain of CD4
that do not interfere with its physiological role might pro-
vide an effective means to prevent HIV infection. Here, we
report on the development and characterization of a CD4
antibody that blocks HIV/SIV infection by binding to the
gp120 binding domain of CD4.
Methods
A mouse monoclonal antibody against primate CD4
(mAb2D5) was generated and screened for blocking of
HIV/SIV envelope mediated entry into target cells using a
pseudotyped lentiviral entry assay. The mAb2D5 was
characterized for its ability to block T cell immune
responses in vitro. The crystal structure of the mAb2D5 Fab
complexed with the two N-terminal domains of CD4 was
determined to 3.6 Å using molecular replacement. Finally,
the Ab was passively administered to rhesus macaques
and monitored for toxicity, mAb2D5 serum levels and
CD4 receptor occupancy.
Results
The CD4 antibody, mAb2D5, inhibited HIV/SIV envelope
mediated entry in to target cells at concentrations of 1–10
μg/ml and was not associated with the inhibition of
immune functions associated with CD4. The crystal struc-
ture of the complex between the mAb2D5 Fab and CD4
reveals an epitope on domain 1 of CD4 that partially over-
laps with the binding site for gp120 and is therefore able
to directly inhibit interaction between CD4 and HIV
envelop. Passive transfer of mAb2D5 to rhesus macaques
did not deplete CD4+ T cells from the peripheral blood
and showed high receptor occupancy. Challenge studies
are planned, and the available results regarding its ability
to inhibit SHIV162P3 infection will be described.
Conclusion
The mAb2D5 potently inhibits HIV and SIV replication in
vitro and is safely tolerated by monkeys. The crystal struc-
ture provides insight into its mechanism of viral entry
inhibition.
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